Company Filing History:
1 out of 1 
1 out of 1 Years Active: 2025
Title: Xihong Liu: Innovator in Multi-Target Kinase Inhibitors
Introduction
Xihong Liu is a prominent inventor based in Guangdong, China, known for his significant contributions to the field of pharmaceutical sciences. His innovative approach towards developing effective treatments has led to the creation of a unique multi-target kinase inhibitor, a breakthrough that holds promise for patients suffering from various cancers.
Latest Patents
Xihong Liu holds a patent for a multi-target kinase inhibitor, along with its pharmaceutical composition and preparation method. This invention specifically addresses the enzymatic activity of several key kinases, namely RET, VEGFR3, and PDGFRA. The active components of the pharmaceutical formulation account for 1-50 wt % of the composition and are designed to inhibit the signaling pathways responsible for several types of cancers, including breast, respiratory tract, brain, reproductive organs, and more. This patent is pivotal in providing therapeutic strategies for patients facing dire health challenges due to abnormal signal transduction pathways associated with kinases.
Career Highlights
Throughout his career, Xihong Liu has been associated with leading biotechnology firms, including Guangzhou Liushun Biotechnology Co., Ltd. and Beijing Beikehuaxia Biomedical Technology Co., Ltd. His work in these organizations has enabled him to leverage cutting-edge technology and research to develop innovative treatments.
Collaborations
Xihong Liu has collaborated with notable professionals in the field, such as Bing Liu and Jingsi Dai. Together, they have contributed to advancing research and development in pharmaceutical sciences, significantly influencing therapeutic approaches to complex diseases.
Conclusion
Xihong Liu stands out as an inventive force in the pharmaceutical industry. His patent for a multi-target kinase inhibitor exemplifies the potential for targeted therapies in cancer treatment. With his extensive professional background and collaborative efforts, Liu continues to play a critical role in driving innovations that may one day enhance patient outcomes globally.